Company: PACB
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001299130-25-000090
Chunk: 105

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 105
---
     | PEO 2         |     |           |     |  $1,717,050 |     |                                  |     | $(551,250)    |     |                                                       |     |  $3,891,000 |     |                                                               |   |      $592,015 |     |                                                 |   | $1,945,500 |     |                                                             |   |   $1,061,203 |     |                                               |   | $(257,000)   |
| 2020 |     | Non-PEO NEOs* |     |           |     |  $1,855,694 |     |                                  |     | $(1,535,473)  |     |                                                       |     |  $4,481,588 |     |                                                               |   |      $138,827 |     |                                                 | — |            |     |                                                             |   |     $(8,737) |     |                                               |   | $(182,732)   |

* Presented on an averaged basis

(a) For purposes of the adjustments to determine “compensation actually paid”, we computed the fair value of equity awards as of each measurement date using valuation assumptions and methodologies (including expected term, volatility, dividend yield and risk-free interest rates) that are consistent with those used to estimate fair value at grant under U.S. GAAP; provided that we made certain adjustments to the valuation assumptions used to calculate option fair values from those disclosed at the time of grant, including to the risk-free rate due to macroeconomic changes between the grant date and valuation dates, the option term in order to incorporate the passage of time in the awards’ life and by the degree to which the option was in or out of the money, the volatilities due to macroeconomic changes in the market for our common stock between the grant date and valuation dates, and to the stock price on the valuation date due to changes in our stock price. All other valuation assumptions are not materially different from the grant-date assumptions and there were no changes in calculation methodology. For additional details on the valuation assumptions used at grant, see Note 9. “Stockholders’ Equity” to the consolidated financial statements included in our Annual Report.

(4) The peer group used for relative TSR is the Nasdaq Biotechnology Index, which is the same peer group we use for the stock performance graph included in our Annual Report pursuant to Item 201(e) of Regulation S-K.

(5) The company-selected measure is revenue, as described above